ASX ANNOUNCEMENT

14 March 2014

LITIGATION: UPDATE

Invion Limited (ASX: IVX) provides the following update to Shareholders regarding legal proceedings commenced in February 2012, against former officers of the Company:

The Company has presently withdrawn its bankruptcy notices against the Defendants, however it has reserved its rights to re-lodge the bankruptcy notices at a date subsequent to the Supreme Court trial, which is due to commence on 5 May 2014.

The Board remains of the view that the Defendants are required to pay the sum of approximately $67,000 for the costs of the interlocutory matters, pursuant to final orders received from the Supreme Court of Queensland and the Court of Appeal on 17 February 2014.

For and on behalf of the Board of Invion Limited

Melanie Farris
COMPANY SECRETARY

About Invion Limited
Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.